Compare CORT & DRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | DRS |
|---|---|---|
| Founded | 1998 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.8B |
| IPO Year | 2001 | 2021 |
| Metric | CORT | DRS |
|---|---|---|
| Price | $108.64 | $34.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $141.00 | $53.18 |
| AVG Volume (30 Days) | 654.4K | ★ 887.3K |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.06% |
| EPS Growth | N/A | ★ 28.75 |
| EPS | 0.09 | ★ 0.55 |
| Revenue | $761,407,000.00 | ★ $3,648,000,000.00 |
| Revenue This Year | $50.53 | $8.27 |
| Revenue Next Year | $48.90 | $7.02 |
| P/E Ratio | $1,294.39 | ★ $61.64 |
| Revenue Growth | 12.79 | ★ 12.80 |
| 52 Week Low | $28.66 | $32.43 |
| 52 Week High | $126.38 | $50.59 |
| Indicator | CORT | DRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 30.12 |
| Support Level | $108.33 | N/A |
| Resistance Level | $122.93 | $37.75 |
| Average True Range (ATR) | 5.02 | 1.00 |
| MACD | -0.88 | -0.08 |
| Stochastic Oscillator | 9.05 | 19.69 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. It is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.